top of page
Search
  • Writer's pictureA2A Pharma
    • Feb 7, 2020
    • 1 min read

A2A / Daewoong Pharmaceutical Oncology Agreement

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery.


LEARN MORE




257 views0 comments

Recent Posts

See All

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE

bottom of page